Matching articles for "NOAC"
Drugs for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 9, 2019; (Issue 1580)
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently...
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently updated.
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • December 3, 2018; (Issue 1561)
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular...
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular events in
patients with chronic coronary artery disease (CAD)
or peripheral artery disease (PAD). Rivaroxaban is
the first direct oral anticoagulant to be approved for
this indication. It was approved earlier for prevention
and treatment of deep vein thrombosis (DVT) or
pulmonary embolism (PE) and for prevention of stroke
and systemic embolism in patients with nonvalvular
atrial fibrillation.
Andexxa - An Antidote for Apixaban and Rivaroxaban
The Medical Letter on Drugs and Therapeutics • June 18, 2018; (Issue 1549)
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor...
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor Xa
inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto).
Andexanet alfa is the second antidote for a direct oral
anticoagulant to become available in the US, and the
fi rst for factor Xa inhibitors. Idarucizumab (Praxbind)
was approved in 2015 for reversal of the anticoagulant
effect of the direct thrombin inhibitor dabigatran
etexilate (Pradaxa). Andexanet alfa has not been
approved to date for reversal of anticoagulation with
the direct factor Xa inhibitors edoxaban (Savaysa) or
betrixaban (Bevyxxa).
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US guidelines
for treatment of VTE were published in 2016.
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
...
View the Comparison Table: Some Oral Anticoagulants for VTE
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
The Medical Letter on Drugs and Therapeutics • January 1, 2018; (Issue 1537)
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who...
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted mobility
and other risk factors for VTE. Betrixaban is the
first oral anticoagulant to be approved in the US for
this indication.
Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • February 27, 2017; (Issue 1515)
With the widespread adoption of the CHA2DS2-VASc
scoring system, oral anticoagulation therapy is
now recommended for all patients ≥75 years old
with nonvalvular atrial fibrillation. Atrial...
With the widespread adoption of the CHA2DS2-VASc
scoring system, oral anticoagulation therapy is
now recommended for all patients ≥75 years old
with nonvalvular atrial fibrillation. Atrial fibrillation
has, however, been associated with an increased
risk of falls, and older patients starting warfarin for
atrial fibrillation have a high rate of hospitalization
for intracranial bleeding. Many practitioners are
reluctant, therefore, to prescribe an oral anticoagulant
for elderly patients who are at high risk for falls.
Which Oral Anticoagulant for Atrial Fibrillation?
The Medical Letter on Drugs and Therapeutics • April 11, 2016; (Issue 1492)
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral...
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral anticoagulants.
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • March 30, 2015; (Issue 1465)
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic...
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation. It is the
fourth new oral anticoagulant to be approved for VTE
and nonvalvular atrial fibrillation.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • July 7, 2014; (Issue 1446)
The treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. New US
guidelines for the management of atrial fibrillation
have recently been...
The treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. New US
guidelines for the management of atrial fibrillation
have recently been published.